

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1297214
<b>Application Number:</b>	10528806
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	6218
<b>Title of Invention:</b>	Inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases
<b>First Named Inventor/Applicant Name:</b>	Jan Menne
<b>Customer Number:</b>	26111
<b>Filer:</b>	Kavita B. Lepping/Vilma Cruz
<b>Filer Authorized By:</b>	Kavita B. Lepping
<b>Attorney Docket Number:</b>	2376.0010000/SRL/TAC
<b>Receipt Date:</b>	07-NOV-2006
<b>Filing Date:</b>	14-JUN-2005
<b>Time Stamp:</b>	12:03:46
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	Power of Attorney	Power_of_Atty.pdf	40961	no	1

**Warnings:**

<b>Information:</b>					
2	Power of Attorney	Statement.pdf	43679	no	1
<b>Warnings:</b>					
<b>Information:</b>					
3	Information Disclosure Statement (IDS) Filed	IDS.pdf	162711	no	4
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
4	Foreign Reference	DE19740384.pdf	245710	no	5
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	WO9707787.pdf	898021	no	26
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	WO2005027629.pdf	3168642	no	41
<b>Warnings:</b>					
<b>Information:</b>					
7	Foreign Reference	DE3924538.pdf	330400	no	5
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	DE69600784.pdf	1587808	no	25
<b>Warnings:</b>					
<b>Information:</b>					
9	Foreign Reference	DE3914764.pdf	1150139	no	17
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Menne.pdf	105720	no	1

<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	XP008029528.pdf	28881	no	1
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	XP008029526.pdf	132753	no	1
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Ningling_Kang_et_al.pdf	940570	no	14
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	XP002278387.pdf	56796	no	1
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	XP002292425.pdf	42318	no	1
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	XP008034017.pdf	147290	no	1
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	XP002292426.pdf	69322	no	2
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	XP002292427.pdf	67478	no	2
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	XP002292428.pdf	57429	no	1

**Warnings:****Information:****Total Files Size (in bytes):**

9276628

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.